{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"2","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"3","value":"0"}]}],"title":"Excessive bleeding"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"3","value":"1"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"3","value":"0"}]}],"title":"Delayed healing"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"4","value":"1"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"3","value":"0"}]}],"title":"Wound dehiscence"}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"214"}],"units":"Participants"}],"description":"Assessed by physician observation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Factor B is the addition or not of bevacizumab: the experimental regimens included bevacizumab (Arms 2 \\& 4).","id":"OG000","title":"Factor B: Bevacizumab"},{"description":"Factor B is the addition or not of bevacizumab: the control regimens did not include bevacizumab (Arms 1 \\& 3)","id":"OG001","title":"Factor B: No Bevacizumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"at definitive surgery, up to 28 weeks","title":"Incidence and Severity of Post-op Complications, Namely Excessive Bleeding, Delayed Wound Healing, and Wound Dehiscence.","type":"SECONDARY","unitOfMeasure":"percentage of participants with event"}